Compile Data Set for Download or QSAR
Report error Found 582 Enz. Inhib. hit(s) with all data for entry = 12565
Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709667(2-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.0300nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458557(US10745401, Example 31 | US11466007, Example 31 | ...)
Affinity DataKi:  0.0800nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709772(2-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.0800nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458588(US10745401, Example 62 | US11466007, Example 62 | ...)
Affinity DataKi:  0.100nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458582(US10745401, Example 56 | US11466007, Example 56 | ...)
Affinity DataKi:  0.110nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458613(US10745401, Example 87 | US11466007, Example 87 | ...)
Affinity DataKi:  0.120nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458694(US10745401, Example 167 | US11466007, Example 167 ...)
Affinity DataKi:  0.140nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458661(US10745401, Example 135 | US11466007, Example 135 ...)
Affinity DataKi:  0.150nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458591(US10745401, Example 65 | US11466007, Example 65 | ...)
Affinity DataKi:  0.150nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458634(2-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.160nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458693(US10745401, Example 166 | US11466007, Example 166 ...)
Affinity DataKi:  0.170nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458695(US10745401, Example 168 | US11466007, Example 168 ...)
Affinity DataKi:  0.180nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458551(US10745401, Example 25 | US11466007, Example 25 | ...)
Affinity DataKi:  0.190nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458605(US10745401, Example 79 | US11466007, Example 79 | ...)
Affinity DataKi:  0.190nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458570(US10745401, Example 44 | US11466007, Example 44 | ...)
Affinity DataKi:  0.220nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458555(US10745401, Example 29 | US11466007, Example 29 | ...)
Affinity DataKi:  0.230nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458577(US10745401, Example 51 | US11466007, Example 51 | ...)
Affinity DataKi:  0.230nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458587(US10745401, Example 61 | US11466007, Example 61 | ...)
Affinity DataKi:  0.230nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458603(US10745401, Example 77 | US11466007, Example 77 | ...)
Affinity DataKi:  0.240nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709767(7-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.25nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458651(US10745401, Example 125 | US12180213, Example 125)
Affinity DataKi:  0.270nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458570(US10745401, Example 44 | US11466007, Example 44 | ...)
Affinity DataKi:  0.330nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458718(5-{2-[4-(1,2-Benzoisoxazol-3-yl)piperidin-1-yl]eth...)
Affinity DataKi:  0.340nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458563(5-{2-[4-(1,2-Benzoisoxazol-3-yl)piperidin-1-yl]eth...)
Affinity DataKi:  0.370nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458600(US10745401, Example 74 | US11466007, Example 74 | ...)
Affinity DataKi:  0.380nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458679(US10745401, Example 152 | US11466007, Example 152 ...)
Affinity DataKi:  0.380nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709772(2-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.400nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458630(US10745401, Example 104 | US11466007, Example 104 ...)
Affinity DataKi:  0.410nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458719(5-{2-[4-(1,2-Benzoisoxazol-3-yl)piperidin-1-yl]eth...)
Affinity DataKi:  0.410nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458562(5-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.450nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458585(US10745401, Example 59 | US11466007, Example 59 | ...)
Affinity DataKi:  0.450nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458652(US10745401, Example 126 | US11466007, Example 126 ...)
Affinity DataKi:  0.450nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709667(2-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.460nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458591(US10745401, Example 65 | US11466007, Example 65 | ...)
Affinity DataKi:  0.460nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458591(US10745401, Example 65 | US11466007, Example 65 | ...)
Affinity DataKi:  0.460nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458557(US10745401, Example 31 | US11466007, Example 31 | ...)
Affinity DataKi:  0.470nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458629(5-{2-[4-(1,2-Benzoisoxazol-3-yl)piperidin-1-yl]eth...)
Affinity DataKi:  0.470nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458645(US10745401, Example 119 | US11466007, Example 119 ...)
Affinity DataKi:  0.480nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458536(US10745401, Example 10 | US11466007, Example 10 | ...)
Affinity DataKi:  0.490nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458541(US10745401, Example 15 | US11466007, Example 15 | ...)
Affinity DataKi:  0.510nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458591(US10745401, Example 65 | US11466007, Example 65 | ...)
Affinity DataKi:  0.520nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458599(US10745401, Example 73 | US11466007, Example 73 | ...)
Affinity DataKi:  0.540nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458617(US10745401, Example 91 | US11466007, Example 91 | ...)
Affinity DataKi:  0.570nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458716(5-{2-[4-(1,2-Benzoisoxazol-3-yl)piperidin-1-yl]eth...)
Affinity DataKi:  0.590nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458696(US10745401, Example 169 | US11466007, Example 169 ...)
Affinity DataKi:  0.600nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM709747(US12180213, Example 82)
Affinity DataKi:  0.610nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458562(5-{2-[4-(1,2-Benzoisothiazol-3-yl)piperazin-1-yl]e...)
Affinity DataKi:  0.620nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 1A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458555(US10745401, Example 29 | US11466007, Example 29 | ...)
Affinity DataKi:  0.680nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458589(US10745401, Example 63 | US11466007, Example 63 | ...)
Affinity DataKi:  0.690nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Sumitomo Pharma

US Patent
LigandPNGBDBM458630(US10745401, Example 104 | US11466007, Example 104 ...)
Affinity DataKi:  0.690nMAssay Description:Binding inhibition rate for 5-HT1A receptor (%)=100−100×{(Binding amount of [3H]8-OH-DPAT in the presence of test compound)}−(Binding amount of [3H]8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/12/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 582 total ) | Next | Last >>
Jump to: